Edwards receives European approval for advanced Sapien 3 valve

Published on:

Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has received CE Mark in Europe and is initiating the launch of its most advanced transcatheter aortic valve, the Edwards SAPIEN 3 valve.

The SAPIEN 3 valve builds upon Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The new valve has an outer skirt -- a cuff of fabric surrounding the valve frame -- providing a seal to address paravalvular leak. The effectiveness of this solution is supported by the limited clinical experience(1, 2), as detailed in two first-in-human feasibility studies, which demonstrated that significant paravalvular leak was eliminated during transcatheter aortic valve implantation (TAVI).

The SAPIEN 3 valve is the only commercial transcatheter heart valve that can be delivered through a low-profile 14 French expandable sheath (eSheath), which has shown through early clinical experience a low rate of complications(1, 2). The valve can be implanted through multiple approaches: transfemoral, transapical or transaortic. Once implanted, the discreet valve anchors in the aortic annulus.

"European physicians have been eagerly awaiting the launch of the Edwards SAPIEN 3 valve, and we are very excited to make it available today. It has a unique design intended to provide a simpler procedure, along with fewer post-procedural complications and a faster recovery for patients," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves. "Based on our clinical leadership in transcatheter heart valves, we believe the SAPIEN 3 valve's characteristics and procedural refinements have the potential to transform TAVI for both physicians and patients."

In the United States, the Edwards SAPIEN 3 valve is an investigational device being studied in the PARTNER II Trial and is not yet available for sale in the country.

Related Content

How TAVR valve choice impacts outcomes when treating type 1 bicuspid AS
Medtronic using AI to identify more TAVR patients in need
SAVR linked to higher 10-year survival rate than TAVR for low-risk patients
9 key takeaways from AHA 2024 in Chicago
Redo TAVR: The impact of implanting balloon-expandable valves in failed self-expanding valves
Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."